Olmesartan
Clinical data | |
---|---|
Trade names | Benicar |
Other names | Olmesartan medoxomil |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603006 |
License data |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 26% |
Metabolism | Liver (cannot be removed by hemodialysis) |
Elimination half-life | 13 hours |
Excretion | Kidney 40%, bile duct 60% |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Olmesartan, sold under the brand name Benicar among others, is a
Common side effects include dizziness,
It was patented in 1991 and came into medical use in 2002.
Medical uses
In the United States, olmesartan is
Olmesartan is used for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.[8] The US Food and Drug Administration (FDA) has determined that the benefits of olmesartan continue to outweigh its potential risks when used for the treatment of people with high blood pressure according to the drug label.[9]
Contraindications
Adverse effects
The incidence of adverse effects with olmesartan is reported as similar to placebo; the only adverse effect that occurred in >1% of patients treated with it and more frequently than placebo was
Chemistry
An ester
History
It was patented in 1991 and came into medical use in 2002.[4]
Society and culture
Brand names
Olmesartan and Sevikar HCT combined is marketed worldwide by Daiichi Sankyo, in India by Abbott Healthcare Pvt. Ltd. under the trade name WinBP, by Zydus Cadila under the trade name Olmy, by Ranbaxy Laboratories Ltd. under the trade name Olvance, Olsar by Unichem Laboratories and in Canada by Schering-Plough as Olmetec. The marketing rights to the brand names Benicar, Benicar HCT, Azor, and Tribenzor in the United States were transferred from Daiichi Sankyo to Cosette in January 2022.[14]
Several preparations containing olmesartan and other antihypertensives are available. Teva Pharmaceuticals produces a formulation containing olmesartan,
Research
Olmesartan has demonstrated potential benefits in reducing the progression of atherosclerotic buildup in arteries. In large randomized placebo-controlled or active drug-controlled studies conducted in participants with hypertension, stable angina, or type 2 diabetes, long-term treatment with olmesartan has been shown to reduce the levels of markers of vascular inflammation.[16] This effect was also observed in a high-cholesterol primate test model.[17]
References
- ^ a b c d "Benicar- olmesartan medoxomil tablet, film coated". DailyMed. 7 September 2022. Retrieved 14 April 2023.
- ^ a b c d e f "Olmesartan Medoxomil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "Olmesartan Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ ISBN 9783527607495.
- ISBN 9780857113382.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Olmesartan - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ "Benicar (olmesartan medoxomil)". RxList Inc. 5 July 2007. Retrieved 22 July 2010.
- ^ "FDA Alert: Benicar (olmesartan): Ongoing Safety Review". Drugs.com. Retrieved 27 June 2013.
- S2CID 260206339.
- S2CID 20614874.
- PMID 22728033.
- PMID 17692338.
- ^ "Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo". Cosette Pharma (Press release). 18 January 2022. Retrieved 14 April 2023.
- ^ "OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE – olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet, film coated". DailyMed. U.S. National Library of Medicine.
- PMID 30358114.
- S2CID 23755806.